TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7909912
Drug: No beta‐adrenoceptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: No beta‐adrenoceptor blocker administered
Study: 7909912
Drug: Propranolol administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol administered during recovery from exercise
Study: 2885802
Drug: Erythromycin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (50 mg/kg/day divided in 2 doses for 10 days)
Study: 28945992
Drug: 2000 U
Normalized name: lipase 2000 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000 U of cholecalciferol daily for 4 months
Study: 25759545
Drug: Tenofovir disoproxil
Normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tenofovir disoproxil fumarate (TDF) 300 mg/d orally
Study: 25759545
Drug: LAM plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAM plus ADV (LAM 100 mg/d orally + ADV 10 mg/d orally)
Study: 21094030
Drug: Aspirin (50mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (50mg per day) and sanchitongshu capsule (200mg three times a day)
Study: 21094030
Drug: Aspirin (50mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (50mg per day) and placebo capsule
Study: 19127598
Drug: Soy isoflavone
Normalized name: soy isoflavone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy isoflavone supplements
Study: 17455121
Drug: Strength Training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strength Training (ST: twice a week)
Study: 14749647
Drug: Sustained-release dinoprostone
Normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sustained-release dinoprostone with concurrent low-dose oxytocin
Study: 14749647
Drug: Multidosing of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidosing of misoprostol (25 microg every 4 hours) followed by high-dose oxytocin
Study: 12197993
Drug: Beef-containing (BC)
Normalized name: Beef
DrugBank: Beef (DB10509)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beef-containing (BC) diet, n = 10, 0.6 g protein.kg(‐1).d(‐1) from beef
Study: 12197993
Drug: Lactoovovegetarian (LOV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactoovovegetarian (LOV) diet, n = 11, 0.6 g protein.kg(‐1).d(‐1) from textured vegetable protein (soy) sources
Study: 10220834
Drug: High titers
Normalized name: Immune Globulin (Human) containing high titers of West Nile virus antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: High titers of anti-IL-8 antibody subclasses and complexes
Study: 2203181
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg natamycin by nebuliser twice daily for one year
Study: 2203181
Drug: Placebo by
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo by nebuliser twice daily for one year
Study: 28425312
Drug: Intrathecal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal administration of PNU-120596 (8 µg/kg, 15 min before surgery)
Study: 28425312
Drug: Intrathecal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal administration of PNU-120596
Study: 28425312
Drug: Intrathecal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal administration of K+‐Cl‐ cotransporter‐2 inhibitor VU0240551
Study: 25824475
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) performed three times a week
Study: 15493396
Drug: Valacyclovir (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valacyclovir (2 grams taken twice on the day of dental treatment and 1 g taken twice the next day)
Study: 11189690
Drug: Quality control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quality control procedures for cancer screening tests (digital rectal examination, ovarian palpation examination, transvaginal ultrasound, chest X-ray, flexible sigmoidoscopy)
Study: 9194104
Drug: Cefpodoxime-proxetil or
Normalized name: Cefpodoxime Proxetil
DrugBank: Cefpodoxime (DB01416)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefpodoxime-proxetil or Amoxicillin-clavulanate
Study: 1347336
Drug: M‐CH (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: M‐CH (50 mg mitomycin intraoperatively)
Study: 3912787
Drug: Progressive relaxation
Normalized name: Relax-DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progressive relaxation therapy during a 3-week interval
Study: 3912787
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment followed by progressive relaxation therapy
Study: 24233255
Drug: Prebiotics enriched
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prebiotics enriched formula containing dietary oligosaccharides (scGOS/lcFOS) at a concentration of 0.8 g/100 ml
Study: 22660441
Drug: Fimasartan (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fimasartan (single dose)
Study: 22660441
Drug: Fimasartan (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fimasartan (daily for 30 days)
Study: 20030830
Drug: Exercise tolerance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise tolerance testing followed by coronary angiography and treatment (percutaneous stenting or surgery) if positive results are found.
Study: 20030830
Drug: Best medical/behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best medical/behavioral therapy offered to the exercise testing group.
Study: 20030830
Drug: Best medical/behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best medical/behavioral therapy offered to the control group (regular follow-up at diabetes outpatient services).
Study: 9455667
Drug: Operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative treatment (segmental fusion)
Study: 2646131
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment of enuresis alarm and 20 micrograms intranasal desmopressin
Study: 28372680
Drug: Spinal anesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anesthesia (intrathecal 0.5% hyperbaric bupivacaine 12.5 mg and 25 μg fentanyl)
Study: 28372680
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia (intravenous analgesia, propofol, and rocuronium followed by endotracheal intubation)
Study: 23271674
Drug: Immediate empirical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate empirical therapy with voriconazole
Study: 23271674
Drug: Deferred therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferred therapy (placebo)
Study: 17926205
Drug: Non‐anaesthetic gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non‐anaesthetic gel
Study: 17926205
Drug: Anaesthetic gel
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anaesthetic gel (Instillagel)
Study: 9561593
Drug: artesunate 600
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: artesunate 600 mg over 2 days and mefloquine 1,250 mg in divided doses
Study: 9561593
Drug: artemether 640
Normalized name: Artemether
DrugBank: Artemether (DB06697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: artemether 640 mg over 2 days and mefloquine 1,250 mg in divided doses
Study: 9561593
Drug: artesunate alone
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: artesunate alone 700 mg over 5 days
Study: 9561593
Drug: artemether alone
Normalized name: Artemether
DrugBank: Artemether (DB06697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: artemether alone 800 mg over 5 days
Study: 9561593
Drug: mefloquine 1,250
Approvals — FDA: no, EMA: no, PMDA: no
Description: mefloquine 1,250 mg in divided doses
Study: 9561593
Drug: artesunate 600
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: artesunate 600 mg over 2 days and mefloquine 750 mg
Study: 1529904
Drug: Flecainide (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flecainide (300 mg/day)
Study: 3872627
Drug: Ceftriaxone 500
Normalized name: ceftriaxone 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 500 mg in a single intramuscular dose
Study: 3872627
Drug: Trimethoprim 160
Normalized name: trimethoprim 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim 160 mg-800 mg of sulfamethoxazole orally twice daily for 7 days
Study: 27788310
Drug: Dose-increment group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-increment group (olanzapine doubled to 20 mg/d or risperidone doubled to 6 mg/d)
Study: 27788310
Drug: Continuation group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuation group (olanzapine 10 mg/d or risperidone 3 mg/d)
Study: 27788310
Drug: Dose-increment group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-increment group
Study: 23365557
Drug: Exenatide 10
Normalized name: EXENATIDE 10MCG/DOSE 2.4ML 60D PEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide 10 μg twice daily (EX10BID)
Study: 23365557
Drug: Liraglutide 1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide 1.2 mg once daily (LIR1.2)
Study: 18955428
Drug: Aquatic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aquatic therapy (Ai Chi and Halliwick methods)
Study: 18955428
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (gym exercises)
Study: 11426917
Drug: Montelukast, Zafirlukast,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast, Zafirlukast, Zileuton (antileukotriene agents)
Study: 11426917
Drug: Antileukotriene agents
Normalized name: ANTIASTHMA,ANTILEUKOTRIENES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antileukotriene agents in combination with low-dose or high-dose corticosteroids
Study: 11426917
Drug: Antileukotriene agents
Normalized name: ANTIASTHMA,ANTILEUKOTRIENES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antileukotriene agents
Study: 171780
Drug: Tinidazole 800
Normalized name: Tinidazole
DrugBank: Tinidazole (DB00911)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tinidazole 800 mg t.d.s. for 5 days
Study: 31825067
Drug: Continuous energy
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous energy restriction (CER) - 25% daily energy restriction
Study: 26384978
Drug: Cognitive-Behavioral Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-Behavioral Therapy (CBT) - Coping Cat
Study: 15103438
Drug: fosfluconazole (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: fosfluconazole (1000 mg bolus intravenous injection)
Study: 15103438
Drug: fluconazole (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: fluconazole (800 mg intravenous infusion)
Study: 12234028
Drug: Famotidine 40
Normalized name: famotidine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine 40 mg preoperatively for 10-14 days
Study: 8088258
Drug: Gabapentin (Neurontin)
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin (Neurontin) as add-on therapy at dosages of 600-2400 mg/day
Study: 8088258
Drug: Gabapentin (Neurontin)
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin (Neurontin) as add-on therapy
Study: 3668801
Drug: oral solution
Normalized name: Oral Solution
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral solution
Study: 2776093
Drug: film‐coated tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: film‐coated tablets
Study: 2776093
Drug: enteric‐coated tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: enteric‐coated tablets
Study: 30383097
Drug: Young fresh
Normalized name: Peroxi-Fresh
Approvals — FDA: no, EMA: no, PMDA: no
Description: Young fresh frozen plasma (yFFP) from male donors, 1 unit (approximately 250 mL) infused once weekly for 4 weeks
Study: 30383097
Drug: Saline (placebo),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (placebo), 250 mL infused once weekly for 4 weeks
Study: 28294641
Drug: liraglutide added
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: liraglutide added to basal insulin
Study: 25841891
Drug: Intramuscular procaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular procaine benzylpenicillin and gentamicin once per day for 7 days (group A)
Study: 25841891
Drug: Intramuscular gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular gentamicin once per day and oral amoxicillin twice per day for 7 days (group B)
Study: 25841891
Drug: Intramuscular procaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular procaine benzylpenicillin and gentamicin once per day for 2 days, then oral amoxicillin twice per day for 5 days (group C)
Study: 25841891
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (standard treatment)
Study: 21671851
Drug: Disease-modifying drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disease-modifying drugs (DMDs) for RRMS
Study: 17364435
Drug: Telephone administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telephone administration of ALSFRS-R
Study: 15051844
Drug: Multiple micronutrient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple micronutrient supplements (MM), n = 142
Study: 15051844
Drug: Iron-only supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron-only supplements (FE), n = 148
Study: 11173790
Drug: GV 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: GV 800 mg/400 mg
Study: 11173790
Drug: GV 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: GV 800 mg/200 mg
Study: 9060194
Drug: Ethanol (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0.75 ml/kg)
Study: 2202619
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (4 x 1 tablet a day, 800 mg total daily dose)
Study: 2202619
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (2 x 2 tablets a day, 800 mg total daily dose)
Study: 2202619
Drug: Group C
Normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C (2 x 1 tablet a day, 400 mg total daily dose)
Study: 7196807
Drug: Cisplatin 90
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 90 mg/m2
Study: 7196807
Drug: Cisplatin 30
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 30 mg/m2 and 90 mg/m2
Study: 28910233
Drug: Beef protein
Normalized name: Beef
DrugBank: Beef (DB10509)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beef protein (20 g mixed with plain water once a day)
Study: 28910233
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein (20 g mixed with plain water once a day)
Study: 28910233
Drug: Carbohydrate (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate (20 g mixed with plain water once a day)
Study: 18575293
Drug: Propofol-MCT/LCT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol-MCT/LCT plus 20 mg lidocaine
Study: 10715674
Drug: Primaquine 45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primaquine 45 mg (given on day 8)
Study: 4052276
Drug: Intravenous and
Normalized name: immune globulin intravenous and subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous and oral propranolol (n = 44)
Study: 4052276
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (n = 35)
Study: 30552595
Drug: Reflexology intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reflexology intervention (four weekly sessions, 30 min each)
Study: 29695211
Drug: Oral Nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Nutritional Supplementation (ONS) plus Dietary Counselling (DC)
Study: 23686730
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam (0.5 mg/kg) plus oral ketamine (5 mg/kg)
Study: 23686730
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam (0.5 mg/kg) plus oral placebo
Study: 17055081
Drug: Rate control
Normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rate control with pharmacological heart rate frequency optimization treatment combined with Holter monitoring
Study: 17055081
Drug: Rhythm control
Normalized name: ALUMINUM ZIRCONIUM TRICHLOROHYDREX GLY 180 mg in 1 g TOPICAL STICK [ZUSKA RHYTHM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhythm control with sinus rhythm restoration and sequential antiarrhythmic drug treatment
Study: 12173678
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of tailored mail and telephone counseling
Study: 7789590
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg vaginal PGE2 gel
Study: 7789590
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg intracervical PGE2
Study: 31530607
Drug: Central line
Normalized name: CENTRAL LINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Central line removal at 100 mL/kg/day of enteral intake
Study: 31530607
Drug: Control group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group: Central line removal at 140 mL/kg/day of enteral intake
Study: 25660340
Drug: Progressive Muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progressive Muscle Relaxation therapy (PMR)
Study: 14764189
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy (twice a week for 8 weeks, total of 16 sessions)
Study: 9597863
Drug: Cefazolin (CEZ)
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefazolin (CEZ) administered on the day of operation
Study: 9597863
Drug: Cefazolin (CEZ)
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefazolin (CEZ) administered for 3 days
Study: 9597863
Drug: Cefazolin (CEZ)
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefazolin (CEZ) or cefotiam (CTM) administered for 2 days
Study: 9597863
Drug: Cefazolin (CEZ)
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefazolin (CEZ) or cefotiam (CTM) administered for 4 days
Study: 9597863
Drug: Shorter antimicrobial
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shorter antimicrobial administration periods
Study: 7940731
Drug: T cell
Normalized name: CD4CAR T cells
DrugBank: Anti-CD4 CAR T-cell therapy (DB17281)
Approvals — FDA: no, EMA: no, PMDA: no
Description: T cell depletion using anti-CD8 and anti-CD6 antibodies plus complement (n = 28)
Study: 27793147
Drug: Combined microsavings
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined microsavings and HIV/STI risk reduction intervention (treatment condition)
Study: 20567051
Drug: Pressurized topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pressurized topical oxygen therapy (TWO(2)), 60-minute treatment, five times per week, pressure cycles between 5 and 50 mb
Study: 20567051
Drug: Silver-containing dressing,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silver-containing dressing, changed at least twice per week (control)
Study: 10485768
Drug: Tidal volume
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tidal volume breathing for 3 min at 5 l/min
Study: 10485768
Drug: Four deep
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four deep breaths for 30 s at 5 l/min
Study: 10485768
Drug: Four deep
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four deep breaths for 30 s at 10 l/min
Study: 10485768
Drug: Four deep
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four deep breaths for 30 s at 20 l/min
Study: 10485768
Drug: Eight deep
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eight deep breaths for 60 s at 10 l/min
Study: 7575750
Drug: Alpha-lipoic acid
Normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-lipoic acid (ALA) 1000 mg/Thioctacid/500 ml NaCl
Study: 7575750
Drug: Vehicle control
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle control (500 ml NaCl)
Study: 28545
Drug: ID-540 (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ID-540 (0.5 mg)
Study: 31561819
Drug: 3-monthly replacement
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 3-monthly replacement group
Study: 31561819
Drug: 6-monthly replacement
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 6-monthly replacement group
Study: 27470115
Drug: Dexmedetomidine 1
Normalized name: DEXMEDETOMIDINE 120MCG SUBLINGUAL FILM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 1 µg/kg IV over 10 min before anesthesia induction, followed by 0.7 µg/kg/h infusion during operation
Study: 27470115
Drug: Remifentanil 1
Normalized name: remifentanil 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 1 µg/kg IV bolus with induction of anesthesia, continued 0.25-0.50 µg/kg/min during operation
Study: 23520223
Drug: Postcard intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postcard intervention (eight in 12 months) plus treatment as usual
Study: 21628666
Drug: AS03(A)-adjuvanted H1N1v
Normalized name: AS03 Adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS03(A)-adjuvanted H1N1v vaccine (3.75 μg HA)
Study: 21628666
Drug: Nonadjuvanted H1N1v
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonadjuvanted H1N1v vaccine (15 μg HA)